In vivo functional interaction between phencyclidine binding sites and σ receptors to produce head-weaving behavior in rats

Kiyoyuki Kitaichi, Yukihiro Noda, Takaaki Hasegawa, Hiroshi Furukawa, Toshitaka Nabeshima

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

To investigate the in vivo functional interaction between phencyclidine (1-(1-phenylcyclohexyl)piperidine; PCP) binding sites and σ receptors, we examined the effects of σ receptor ligands on stereotyped head-weaving behavior induced by PCP, a putative PCP/σ receptor ligand, and (+)-5-methyl-10,11-dihydroxy-5H-dibenzo(a,d)cyclo-hepten- 5,10-imine ((+)-MK-801; dizocilpine), a selective PCP binding site ligand, in rats. PCP (7.5 mg/kg, i.p.)-induced head-weaving behavior was inhibited by both N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)-phenyl]- ethylamine (NE-100; 0.03-1.0 mg/kg, p.o.), a selective σ1 receptor ligand, and α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperidine butanol (BMY-14802; 3 and 10 mg/kg, p.o.), a prototype σ receptor ligand, in a dose-dependent manner, whereas NE-100 (0.1-1.0 mg/kg, p.o.) and BMY-14802 (3 and 10 mg/kg, p.o.) did not inhibit dizocilpine (0.25 mg/kg, s.c.)-induced head-weaving behavior. These results suggest that NE-100 and BMY-14802 act via σ receptors. Dizocilpine-induced head-weaving behavior was potentiated by 1,3-di-o-tolyl-guanidine (DTG; 0.03-0.3 μg/kg, i.v.) and (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine ((+)3-PPP; 3 and 6 mg/kg, i.p.), σ12 receptor ligands, as well as by (+)-N-allyl-normetazocine ((+)-SKF-10,047; 8 mg/kg, i.p.), a σ1 receptor ligand, while DTG (0.3 μg/kg, i.v.), (+)-3-PPP (6 mg/kg, i.p.) and(+)-SKF-10,047 (8 mg/kg, i.p.) did not induce this behavior. Potentiation of dizocilpine-induced head-weaving behavior by DTG (0.3 μg/kg, i.v.), (+)-3-PPP (6 mg/kg, i.p.) and (+)-SKF-10,047 (8 mg/kg, i.p.) was completely blocked by NE-100 (0.1 mg/kg, p.o.) and BMY-14802 (10 mg/kg, p.o.). These results suggest that PCP binding sites and σ receptors are involved in PCP-induced head-weaving behavior, and that σ1 receptors play an important role in modulation of the head-weaving behavior.

Original languageEnglish
Pages (from-to)205-211
Number of pages7
JournalEuropean Journal of Pharmacology
Volume318
Issue number2-3
DOIs
Publication statusPublished - 30-12-1996
Externally publishedYes

Fingerprint

Phencyclidine
Dizocilpine Maleate
Binding Sites
Head
Ligands
Phencyclidine Receptors
1-Butanol
Imines
Guanidine
alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol
N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Kitaichi, Kiyoyuki ; Noda, Yukihiro ; Hasegawa, Takaaki ; Furukawa, Hiroshi ; Nabeshima, Toshitaka. / In vivo functional interaction between phencyclidine binding sites and σ receptors to produce head-weaving behavior in rats. In: European Journal of Pharmacology. 1996 ; Vol. 318, No. 2-3. pp. 205-211.
@article{5c3204cc23e84b07870dc6c9ef6b58ba,
title = "In vivo functional interaction between phencyclidine binding sites and σ receptors to produce head-weaving behavior in rats",
abstract = "To investigate the in vivo functional interaction between phencyclidine (1-(1-phenylcyclohexyl)piperidine; PCP) binding sites and σ receptors, we examined the effects of σ receptor ligands on stereotyped head-weaving behavior induced by PCP, a putative PCP/σ receptor ligand, and (+)-5-methyl-10,11-dihydroxy-5H-dibenzo(a,d)cyclo-hepten- 5,10-imine ((+)-MK-801; dizocilpine), a selective PCP binding site ligand, in rats. PCP (7.5 mg/kg, i.p.)-induced head-weaving behavior was inhibited by both N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)-phenyl]- ethylamine (NE-100; 0.03-1.0 mg/kg, p.o.), a selective σ1 receptor ligand, and α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperidine butanol (BMY-14802; 3 and 10 mg/kg, p.o.), a prototype σ receptor ligand, in a dose-dependent manner, whereas NE-100 (0.1-1.0 mg/kg, p.o.) and BMY-14802 (3 and 10 mg/kg, p.o.) did not inhibit dizocilpine (0.25 mg/kg, s.c.)-induced head-weaving behavior. These results suggest that NE-100 and BMY-14802 act via σ receptors. Dizocilpine-induced head-weaving behavior was potentiated by 1,3-di-o-tolyl-guanidine (DTG; 0.03-0.3 μg/kg, i.v.) and (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine ((+)3-PPP; 3 and 6 mg/kg, i.p.), σ1/σ2 receptor ligands, as well as by (+)-N-allyl-normetazocine ((+)-SKF-10,047; 8 mg/kg, i.p.), a σ1 receptor ligand, while DTG (0.3 μg/kg, i.v.), (+)-3-PPP (6 mg/kg, i.p.) and(+)-SKF-10,047 (8 mg/kg, i.p.) did not induce this behavior. Potentiation of dizocilpine-induced head-weaving behavior by DTG (0.3 μg/kg, i.v.), (+)-3-PPP (6 mg/kg, i.p.) and (+)-SKF-10,047 (8 mg/kg, i.p.) was completely blocked by NE-100 (0.1 mg/kg, p.o.) and BMY-14802 (10 mg/kg, p.o.). These results suggest that PCP binding sites and σ receptors are involved in PCP-induced head-weaving behavior, and that σ1 receptors play an important role in modulation of the head-weaving behavior.",
author = "Kiyoyuki Kitaichi and Yukihiro Noda and Takaaki Hasegawa and Hiroshi Furukawa and Toshitaka Nabeshima",
year = "1996",
month = "12",
day = "30",
doi = "10.1016/S0014-2999(96)00771-6",
language = "English",
volume = "318",
pages = "205--211",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

In vivo functional interaction between phencyclidine binding sites and σ receptors to produce head-weaving behavior in rats. / Kitaichi, Kiyoyuki; Noda, Yukihiro; Hasegawa, Takaaki; Furukawa, Hiroshi; Nabeshima, Toshitaka.

In: European Journal of Pharmacology, Vol. 318, No. 2-3, 30.12.1996, p. 205-211.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vivo functional interaction between phencyclidine binding sites and σ receptors to produce head-weaving behavior in rats

AU - Kitaichi, Kiyoyuki

AU - Noda, Yukihiro

AU - Hasegawa, Takaaki

AU - Furukawa, Hiroshi

AU - Nabeshima, Toshitaka

PY - 1996/12/30

Y1 - 1996/12/30

N2 - To investigate the in vivo functional interaction between phencyclidine (1-(1-phenylcyclohexyl)piperidine; PCP) binding sites and σ receptors, we examined the effects of σ receptor ligands on stereotyped head-weaving behavior induced by PCP, a putative PCP/σ receptor ligand, and (+)-5-methyl-10,11-dihydroxy-5H-dibenzo(a,d)cyclo-hepten- 5,10-imine ((+)-MK-801; dizocilpine), a selective PCP binding site ligand, in rats. PCP (7.5 mg/kg, i.p.)-induced head-weaving behavior was inhibited by both N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)-phenyl]- ethylamine (NE-100; 0.03-1.0 mg/kg, p.o.), a selective σ1 receptor ligand, and α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperidine butanol (BMY-14802; 3 and 10 mg/kg, p.o.), a prototype σ receptor ligand, in a dose-dependent manner, whereas NE-100 (0.1-1.0 mg/kg, p.o.) and BMY-14802 (3 and 10 mg/kg, p.o.) did not inhibit dizocilpine (0.25 mg/kg, s.c.)-induced head-weaving behavior. These results suggest that NE-100 and BMY-14802 act via σ receptors. Dizocilpine-induced head-weaving behavior was potentiated by 1,3-di-o-tolyl-guanidine (DTG; 0.03-0.3 μg/kg, i.v.) and (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine ((+)3-PPP; 3 and 6 mg/kg, i.p.), σ1/σ2 receptor ligands, as well as by (+)-N-allyl-normetazocine ((+)-SKF-10,047; 8 mg/kg, i.p.), a σ1 receptor ligand, while DTG (0.3 μg/kg, i.v.), (+)-3-PPP (6 mg/kg, i.p.) and(+)-SKF-10,047 (8 mg/kg, i.p.) did not induce this behavior. Potentiation of dizocilpine-induced head-weaving behavior by DTG (0.3 μg/kg, i.v.), (+)-3-PPP (6 mg/kg, i.p.) and (+)-SKF-10,047 (8 mg/kg, i.p.) was completely blocked by NE-100 (0.1 mg/kg, p.o.) and BMY-14802 (10 mg/kg, p.o.). These results suggest that PCP binding sites and σ receptors are involved in PCP-induced head-weaving behavior, and that σ1 receptors play an important role in modulation of the head-weaving behavior.

AB - To investigate the in vivo functional interaction between phencyclidine (1-(1-phenylcyclohexyl)piperidine; PCP) binding sites and σ receptors, we examined the effects of σ receptor ligands on stereotyped head-weaving behavior induced by PCP, a putative PCP/σ receptor ligand, and (+)-5-methyl-10,11-dihydroxy-5H-dibenzo(a,d)cyclo-hepten- 5,10-imine ((+)-MK-801; dizocilpine), a selective PCP binding site ligand, in rats. PCP (7.5 mg/kg, i.p.)-induced head-weaving behavior was inhibited by both N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)-phenyl]- ethylamine (NE-100; 0.03-1.0 mg/kg, p.o.), a selective σ1 receptor ligand, and α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperidine butanol (BMY-14802; 3 and 10 mg/kg, p.o.), a prototype σ receptor ligand, in a dose-dependent manner, whereas NE-100 (0.1-1.0 mg/kg, p.o.) and BMY-14802 (3 and 10 mg/kg, p.o.) did not inhibit dizocilpine (0.25 mg/kg, s.c.)-induced head-weaving behavior. These results suggest that NE-100 and BMY-14802 act via σ receptors. Dizocilpine-induced head-weaving behavior was potentiated by 1,3-di-o-tolyl-guanidine (DTG; 0.03-0.3 μg/kg, i.v.) and (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine ((+)3-PPP; 3 and 6 mg/kg, i.p.), σ1/σ2 receptor ligands, as well as by (+)-N-allyl-normetazocine ((+)-SKF-10,047; 8 mg/kg, i.p.), a σ1 receptor ligand, while DTG (0.3 μg/kg, i.v.), (+)-3-PPP (6 mg/kg, i.p.) and(+)-SKF-10,047 (8 mg/kg, i.p.) did not induce this behavior. Potentiation of dizocilpine-induced head-weaving behavior by DTG (0.3 μg/kg, i.v.), (+)-3-PPP (6 mg/kg, i.p.) and (+)-SKF-10,047 (8 mg/kg, i.p.) was completely blocked by NE-100 (0.1 mg/kg, p.o.) and BMY-14802 (10 mg/kg, p.o.). These results suggest that PCP binding sites and σ receptors are involved in PCP-induced head-weaving behavior, and that σ1 receptors play an important role in modulation of the head-weaving behavior.

UR - http://www.scopus.com/inward/record.url?scp=0030607667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030607667&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(96)00771-6

DO - 10.1016/S0014-2999(96)00771-6

M3 - Article

C2 - 9016907

AN - SCOPUS:0030607667

VL - 318

SP - 205

EP - 211

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -